## **EXHIBIT A**

**PATENT** Docket No. 235,0020 0101

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): TARLETON et al.

Group Art Unit:

Unassigned

Serial No.:

09/518,156

Examiner:

Unassigned

Filed:

2 March 2000

PROPHYLACTIC AND THERAPEUTIC IMMUNIZATION AGAINST PROTOZOAN For:

INFECTION AND DISEASE

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington D.C. 20231

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 et. seq., the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached 1449 forms is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 forms, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

#### CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Commissioner for Patents. Washington, D.C. 20231, on this September, 2000

Victoria A. Sandberg

Respectfully submitted,

Tarleton et al.

By their Representatives,

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

By:

Minneapolis, MN 55458-1415

Phone: (612)305-1220

Facsimile: (612)305-1228

September 2000

Victoria A. Sandberg

Reg. No. 41,287

Direct Dial (612)305-1226

OMB No. 0651-0011

	Page 1 of 12								
INFORMATION			Att Docket No.: 235.0020 0101		Serial	Serial No.: 09/518,156			
DISCLOSURE									
	STATEMENT Applicant(s): TARLETON et al. 1675					15			
			Fili	ing Date: 2 M	arch 2000	Grou	Group: Unassigned		
	,		U.S	S. PATENT D	OCUMENTS				
Examiner Initial		Document Numbe		Date	Name	Class	SubClass		Date If opriate
		NONE				<b>A</b>			
							\		
		1		T T	T DOCUMENTS		Subillass	T	
	:	Document Numb	er	Date	Country	Class	Sub lass	Yes	No No
		NONE					1		
	THE	r			ors, Title, Date,				
					f a Glycosylphospl				
$\sim$		(February 26, 1			brucei," J. Biol.	Chem., 2/4	(9):5931- 	5938 	
$\sim$		Abrahamsohn, "Cytokines in innate and acquired immunity to <i>Trypanosoma cruzi</i> infection," Braz. J. Med. Biol. Res., 31(1):117-121 (January 1998).							
		Alberti et al., "Specific cellular and humoral immune response in Balb/c mice							
$\sim$		immunised with an expression genomic library of <i>Trypanosoma cruzi</i> ," <u>Vaccine</u> , <u>16(6):608-612</u> (April 1998).							
	Al-Qahtani et al., "A 5' untranslated region which directs accurate and robust								
$\sim$	translation by prokaryotic and mammalian ribosomes," Nuc. Acids Res., 24(6):1173-1174 (1996).								
	Andrews et al., "Presence of antibodies to the major surface glycoprotein of								
~	Trypanosoma cruzi amastigotes in sera from chagasic patients," Am. J. Trop. Med. Hyg., 40(1):46-49 (1989).								
$\sim$		Andrews, "The Acid-Active Hemolysin of <i>Trypanosoma cruzi</i> ," Exp. Parasitol., 71:241-244 (1990).							
	Barry et al., "Protection against mycoplasma infection using expression-library				7				
/ -	immunization," <u>Nature</u> , <u>377</u> (6550):632-635 (1995).								
$\sim$		Barry et al., "Biological features of genetic immunization," <u>Vaccine</u> , <u>15</u> (8):788-791 (1997).							
N	Basombrio, "Trypanosoma cruzi: Partial Prevention of the Natural Infection of				f				
Li	Guinea Pigs with a Killed Parasite Vaccine," Exp. Parasitol., 71:1-8 (1990).								

EXAMINER	Date Considered
MARE NAVARON	6/16/03
	A LINESPERIOR OF THE LOCAL COLUMN

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-FB-A820 Patent and Trademark Office, U.S. Department of Commerce

JMB No. 0651-0011 Page 2 of 12

# **STATEMENT**

Atty. Docket No.: 235.0020 0101 Serial No.: 09/518,156

Applicant(s): TARLETON et al.

Group: Unassigned

Filing Date: 2 March 2000

~	Bharadwaj et al., "Induction of Protective Immune Responses by Immunization with Linear Multiepitope Peptides Based on Conserved Sequences from <i>Plasmodium falciparum</i> Antigens," <u>Infect. Immun.</u> , <u>66</u> (7):3232-3241 (July 1998).
~	Biebinger et al., "A Plasmid Shuttle Vector Bearing an rRNA Promoter is Extrachromosomally Maintained in <i>Crithidia fasciculata</i> ," Exp. Parasitol., 83(2):252-258 (1996).
~	Bliss et al., "IL-12, as an Adjuvant, Promotes a T Helper 1 Cell, but Does Not Suppress a T Helper 2 Cell Recall Response," <u>J. Immunol.</u> , <u>156</u> :(3):887-894 (1996).
~	Brener, "Why Vaccines do not work in Chagas Disease," <u>Parasitol. Today</u> , <u>2</u> (7):196-197 (1986).
	Carpenter et al., "Linearized free maxicircle DNA in <i>Crithidia fasciculata</i> is a product of topoisomerase II-mediated cleavage," Mol. Biochem. Parasitol., 76:115-123 (1996).
~	Chow et al., "Development of Th1 and Th2 Populations and the Nature of Immune Responses to Hepatitis B Virus DNA Vaccines Can Be Modulated by Codelivery of Various Cytokine Genes," J. Immunol., 160(3):1320-1329 (February 1, 1998).
$\sim$	Clayton et al., "Protein Trafficking in Kinetoplastid Protozoa," Microbiol. Rev., 59(3):325-344 (1995).
~	Coburn et al., "Stable DNA transfection of a wide range of trypanosomatids," Mol. Biochem. Parasitol., 46:169-179 (1991).
$\sim$	Conry et al., "Polynucleotide-Mediated Immunization Therapy of Cancer," Seminars Oncol., 23(1):135-147 (1996).
N	Costa et al., "Immunization with a plasmid DNA containing the gene of <i>trans</i> -sialidase reduces <i>Trypanosoma cruzi</i> infection in mice," <u>Vaccine</u> , <u>16</u> (8):768-774 (May 1998).
~	Cross et al., "The Surface <i>Trans</i> -Sialidase Family of <i>Trypanosoma Cruzi</i> ," <u>Ann.</u> Rev. Microbiol., <u>47</u> :385-411 (1993).
$\sim$	DeRisi et al., "Use of a cDNA microarray to analyse gene expression patterns in human cancer," Nature Genet., 14(4):457-460 (1996).
$\sim$	DeRisi et al., "Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale," Science, 278(5338):680-686 (1997).

EXAMINER			Date Considered		
	MARK	NAVARPO	6/16/03		
*Eveminer: Initial if	reference consider	ad whather or not citation	is in conformance with MPFP 609: Draw line through citation if not in		

OMB No. 0651-0011 Page 3 of 12

## INFORMATION DISCLOSURE RADEMN STATEMENT

Arty. D cket No.: 235.0020 0101 | Serial No.: 09/518,156

Applicant(s): TARLETON et al.

Filing Date: 2 March 2000 Group: Unassigned

$\sim$	Donnelly et al., "DNA Vaccines," Ann. Rev. Immunol., 15:617-648 (1997).
~	Endresz et al., "Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization," <u>Vaccine</u> , <u>17(1):50-58</u> (January 1999).
$\sim$	Englund, "The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors," <u>Annu. Rev. Biochem.</u> , <u>62</u> :121-138 (1993).
~	Freedman et al., "Two more independent selectable markers for stable transfection of <i>Leishmania</i> ," Mol. Biochem. Parasitol., 62:37-44 (1993).
~	Fontt et al., "Relationship between granulocyte macrophage-colony stimulating factor, tumour necrosis factor-α and <i>Trypanosoma cruzi</i> infection of murine macrophages," <u>Parasite Immunol.</u> , <u>17(3)</u> :135-141 (1995).
$\sim$	Fontt et al., "Granulocyte-Macrophage Colony-Stimulating Factor: Involvement in Control of <i>Trypanosoma cruzi</i> Infection in Mice," <u>Infect. Immun.</u> , <u>64(8)</u> :3429-3434 (1996).
~	Fontt et al., "Effects of Granulocyte-Macrophage Colony-Stimulating Factor and Tumor Necrosis Factor Alpha on <i>Trypanosoma cruzi</i> Trypomastigotes," <u>Infect. Immun.</u> , 66(6):2722-2727 (June 1998).
~	Fouts et al., "Nucleotide sequence and transcription of a trypomastigote surface antigen gene of <i>Trypanosoma cruzi</i> ," Mol. Biochem. Parasitol., 46:189-200 (1991).
	Fouts et al., " <i>Trypanosoma cruzi</i> trypomastigote surface glycoprotein (TSA-1) mRNA, GenBank Accession No. M58466," (1993).
~	Garg et al., "Proteins with Glycosylphosphatidylinositol (GPI) Signal Sequences Have Divergent Fates during a GPI Deficiency," J. Biol. Chem., 272(19):12482-12491 (1997).
1	Garg et al., "Delivery by <i>Trypanosoma cruzi</i> of Proteins into the MHC Class I Antigen Processing and Presentation Pathway," <u>J. Immunol.</u> , <u>158</u> :3293-3302 (1997).
	Garg et al., "Elicitation of protective immunity to <i>Trypanosoma cruzi</i> using DNA vaccines," Proceedings of the 10 <sup>th</sup> International Congress of Immunology, New Delhi, India, Monduzzi, Bologna pages 1421-1426 (November 1-6, 1998).

EXAMINER	Date Considered
MARK NAVARIO	6/16/03
*Prominent Initial if m. C	1.7

	the state of the s
N	Geissler et al., "Enhancement of Cellular and Humoral Immune Responses to Hepatitis C Virus Core Protein Using DNA-Based Vaccines Augmented with Cytokine-Expressing Plasmids," J. Immunol., 158(3):1231-1237 (1997).
1	Gomes, "PCR and Sero-Diagnosis of Chronic Chagas' Disease," <u>Appl. Biochem.</u> <u>Biotechnol., 66(2):107-119 (1997).</u>
$\sim$	Gurunathan et al., "Vaccination with DNA Encoding the Immunodominant LACK Parasite Antigen Confers Protective Immunity to Mice Infected with <i>Leishmania major</i> ," J. Exp. Med., 186(7):1137-1147 (1997).
~	Ha et al., "Use of the green fluorescent protein as a marker in transfected <i>Leishmania</i> ," Mol. Biochem. Parasitol., 77:57-64 (1996).
~	Hartikka et al., "An Improved Plasmid DNA Expression Vector for Direct Injection into Skeletal Muscle," <u>Human Gene Ther., 7(10):1205-1217 (1996)</u> .
$\sim$	Hoffman et al., "Toward clinical trials of DNA vaccines against malaria," Immunol. Cell Biol., 75(4):376-381 (1997).
~	Hsu et al., "Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness <i>in vivo</i> by genetic immunization," Nat. Med., 2(5):540-544 (1996).
$\sim$	Hudson et al., "Immune response to South American trypanosomiasis and its relationship to Chagas' disease," <u>Brit. Med. Bull.</u> , 41(2):175-180 (1985).
2	lida et al., "Amastigotes of <i>Trypanosoma cruzi</i> escape destruction by the terminal complement components," <u>J. Exp. Med., 169</u> :881-891 (1989).
~	Inverso et al., "Crithidia fasciculata contains a transcribed leishmanial surface proteinase (gp63) gene homologue," Mol. Biochem. Parasitol., 57:47-54 (1993).
	Irvine et al., "Cytokine Enhancement of DNA Immunization Leads to Effective Treatment of Established Pulmonary Metastases," <u>J. Immunol.</u> , <u>156</u> (1):238-245 (1996).
~	Jones et al., "Amplification of a <i>Trypanosoma cruzi</i> DNA sequence from inflammatory lesions in human chagasic cardiomyopathy," <u>Am. J. Trop. Med. Hyg., 48(3):348-357 (1993)</u> .
$\sim$	Jones et al., "Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in <i>Aotus</i> monkeys," <u>Vaccine</u> , <u>17</u> (23-24):3065-3071 (August 6, 1999).

EXAMINER	Date Considered
MARK NAVARO	6/16/03
#Framinan Initial if the factor of the state	in its and a second of the sec

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 5 of 12

	CLOSURE TRA	Ut Mary		
STATEMENT		Applicant(s): TARLETON et al.		
		Filing Date: 2 March 2000	Group: Unassigned	
			i i	
~		Filing Date: 2 March 2000 Group: Unassigned  Kelly et al., "A shuttle vector which facilitates the expression of transfected genes in Trypanosoma cruzi and Leishmania," Nuc. Acids Res., 20(15):3963-3969 (1992)		
~		Kelly, "Trypanosomatid Shuttle Vectors: New Tools for the Functional Dissection of Parasite Genomes," <u>Parasitol. Today</u> , <u>11</u> (12):447-450 (1995).		
~	1 1	, "The Growth and Nutrition of <i>Crith</i> <u>18</u> :621-638 (1958).	ida fasciculata," <u>J. Gen.</u>	
~	1 1	Kierszenbaum and Hudson, "Autoimmunity in Chagas Disease: Cause or Symptom?" Parasitol. Today, 1(1):4-9 (1985).		
$\sim$	Kierszenbau (1986).	Kierszenbaum, "Autoimmunity in Chagas' disease," J. Parasitol., 72(2):201-211		
1	Coadministr	Kim et al., "In Vivo Engineering of a Cellular Immune Response by Coadministration of IL-12 Expression Vector with a DNA Immunogen," J. Immunol., 158(2):816-826 (1997).		
$\sim$	by DNA Vac	Kim et al., "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV," <u>J. Interferon Cytokine Res.</u> , 19(1):77-84 (January 1999).		
	1	Kozak, "Features in the 5' Non-coding Sequences of Rabbit α and β-Globin mRNAs that Affect Translational Efficiency," J. Mol. Biol., 235:95-110 (1994).		
N		Krettli et al., "Resistance against <i>Trypanosoma cruzi</i> associated to anti-living trypomastigote antibodies," <u>J. Immunol., 128(5):2009-2012</u> (1982).		
~	indicates uni	La Flamme et al., "Expression of mammalian cytokines by <i>Trypanosoma cruzi</i> indicates unique signal sequence requirements and processing," Mol. Biochem. Parasitol., 75:25-31 (1995).		
~	and in situ h	Lane et al., "Detection of <i>Trypanosoma cruzi</i> with the polymerase chain reaction and in situ hybridization in infected murine cardiac tissue," <u>Am. J. Trop. Med. Hyg.</u> , 56(6):588-595 (1997).		
	and Rhesus	Le Borgne et al., "In Vivo Induction of Specific Cytotoxic T Lymphocytes in Mice and Rhesus Macaques Immunized with DNA Vector Encoding an HIV Epitope Fused with Hepatitis B Surface Antigen," Virology, 240(2):304-315 (January 20, 1998).		

EXAMINER	Date Considered
MARK NAVAROUS	6/16/03

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**JMB No. 0651-0011** JAN 0 2 200 Page 6 of 12 INFORMATION Docket No.: 235.0020 0101 Serial No.: 09/518,156 **DISCLOSURE STATEMENT** Applicant(s): TARLETON et al. Group: Unassigned

2	LeBowitz et al., "Development of a stable <i>Leishmania</i> expression vector and application to the study of parasite surface antigen genes," <u>Proc. Natl. Acad. Sci. USA</u> , <u>87</u> :9736-9740 (1990).
n	LeBowitz et al., "Simultaneous transient expression assays of the trypanosomatid parasite <i>Leishmania</i> using $\beta$ -galactosidase and $\beta$ -glucuronidase as reporter enzymes," Gene, 103:119-123 (1991).
$\sim$	Ley et al., "The exit of <i>Trypanosoma cruzi</i> from the phagosome is inhibited by raising the pH of acidic compartments," <u>J. Exp. Med., 171</u> :401-413 (1990).
~	Low et al., " <i>Trypanosoma cruzi</i> amastigote surface protein-2 (ASP-2) mRNA, GenBank Accession No. U77951," submitted to Gen Bank on November 11, 1996.
2	Low et al., "Molecular cloning of the gene encoding the 83 kDa amstigote surface protein and its identification as a member of the <i>Trypanosoma cruzi</i> sialidase superfamily," Mol. Biochem. Parasitol., 88(1-2):137-149 (1997).
~	Low et al., "Amastigote Surface Proteins of <i>Trypanosoma cruzi</i> Are Targets for CD8+ CTL," J. Immunol., 160:1817-1823 (February 15, 1998).
	Lowrie et al., "Protection against tuberculosis by a plasmid DNA vaccine," <u>Vaccine</u> , 15(8):834-838 (1997).
~	McCluskie et al., "Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates," Mol. Med., 5(5):287-300 (May 1999).
~	Mensa-Wilmot et al., "A Glycosylphosphatidylinositol (GPI)-Negative Phenotype Produced In <i>Leishmania major</i> by GPI Phospholipase C from <i>Trypanosoma brucei</i> : Topography of Two GPI Pathways," J. Cell Biol., 124(6):935-947 (1994).
1	Mensa-Wilmot et al., "Purification and Use of Recombinant Glycosylphosphatidylinositol-Phospholipase C," Methods Enzymol., 250:641-655 (1995).
~	Meyer zum Büschenfelde et al., " <i>Trypanosoma cruzi</i> induces strong IL-12 and IL-18 gene expression <i>in vivo</i> : correlation with interferon-gamma (IFN-γ) production," Clin. Exp. Immunol., 110(3):378-385 (1997).
	Monaco, "A molecular model of MHC class-I-restricted antigen processing," Immunol. Today, 13(5):173-179 (1992).

Filing Date: 2 March 2000

EXAMINER	Date Considered		
MARK NAVARADO	6/16/03		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION RADES
DISCLOSURE
STATEMENT

Atty. Docket No.: 235.0020 0101 Seriai No.: 09/518,156

Applicant(s): TARLETON et al.

Filing Date: 2 March 2000 Group: Unassigned

$\sim$	Muller et al., "Trypanosoma cruzi: Isolate Dependence in the Induction of Lytic Antibodies in the Mouse and Rabbit," Exp. Parasitol., 61:284-293 (1986).  Nabors et al., "Differential control of IFN-γ and IL-2 production during  Trypanosoma grazi infection" Limmunol, 146(10):3591,3598 (1991)	
2	Nabors et al., "Differential control of IFN-γ and IL-2 production during Trypanosoma cruzi infection," J. Immunol., 146(10):3591-3598 (1991).	
$\sim$	Nagahara et al., "Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27 <sup>kip1</sup> induces cell migration," Nature Med., 4(12):1449-1452 (December 1998).	
$\sim$	Pan et al., "Amastigote and Epimastigote Stage-Specific Components of <i>Trypanosoma cruzi</i> Characterized by Using Monoclonal Antibodies: Purification and Molecular Characterization of an 83-kilodalton Amastigote Protein," <u>J. Immunol.</u> , 143(3):1001-1008 (1989).	
$\sim$	Peterson et al., "Cloning of a major surface-antigen gene of <i>Trypanosoma cruzi</i> and identification of a nonapeptide repeat," Nature, 322:(6079):566-568 (1986).	
N	Rashid et al., "Roles of Gln81 and Cys80 in catalysis by glycosylphosphatidylinositol-phospholipase C from <i>Trypanosoma brucei</i> ," <u>Eur. J. Biochem.</u> , <u>264</u> :914-920 (September 1999).	
~	Raz et al., "Preferential induction of a Th <sub>1</sub> immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization," <u>Proc. Nat'l. Acad. Sci. USA.</u> , <u>93</u> (10):5141-5145 (1996).	
~	Reed, "In vivo administration of recombinant IFN-γ induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental <i>Trypanosoma cruzi</i> infections," J. Immunol., 140(12):4342-4347 (1988).	
N	Reis et al., "An <i>in Situ</i> Quantitative Immunohistochemical Study of Cytokines an IL-2R <sup>+</sup> in Chronic Human Chagasic Myocarditis: Correlation with the Presence of Myocardial <i>Trypanosoma cruzi</i> Antigens," Clin. Immunol. Immunopathol., 83(2):165-172 (1997).	
$\sim$	Rodriguez et al., " <i>Trypanosoma cruzi</i> Infection in B-Cell-Deficient Rats," <u>Infect.</u> <u>Immun.</u> , <u>31(2):524-529 (1981)</u> .	
1	Rötzschke et al., "Exact prediction of a natural T cell epitope," Eur. J. Immunol., 21(10):2891-2894 (1991).	

EXAMINER	Date Considered
MANY NAVARAN	6/16/03

INFORMATION DISCLOSURE STATEMENT

Page 8 of 1

INFORMATION Docket No.: 235.0020 0101 Serial No.: 09/518,156

Applicant(s): TARLETON et al.

Filing Date: 2 March 2000 Group: Unassigned

~	Ruiz et al., "Monoclonal antibodies against the flagellar fraction of epimastigotes of <i>Trypanosoma cruzi</i> : immunoprotection against metacyclic trypomastigotes obtained by immunization of mice with an affinity-purified antigen," Mol. Biochem. Parasitol. 39:117-125 (1990).
N	Santos-Buch et al., "Chapter 8: Pathology of Chagas' Disease," <u>Immunology and Pathogenesis of Trypanosomiasis</u> , Tizard, ed., CRC Press, Boca Raton, Title page, publication page and pages 145-183 (1985).
	Santos et al., "Trypanosoma cruzi surface protein-1 mRNA, GenBank Accession No. U74494," submitted to GenBank on October 15, 1996.
$\sim$	Santos et al., "The identification and molecular characterization of <i>Trypanosoma</i> cruzi amastigote surface protein-1, a member of the <i>trans</i> -sialidase gene superfamily," Mol. Biochem. Parasitol., 86:1-11 (1997).
~	Schenkman et al., "Mucin-like glycoproteins linked to the membrane by glycosylphosphatidylinositol anchor are the major acceptors of sialic acid in a reaction catalyzed by trans-sialidase in metacyclic forms of <i>Trypanosoma cruzi</i> ," Mol. Biochem. Parasitol., 59:293-303 (1993).
$\sim$	Schirmbeck et al., "DNA Vaccine Primes MHC Class I-Restricted, Simian Virus 40 Large Tumor Antigen-Specific CTL in H-2 <sup>d</sup> Mice That Reject Syngeneic Tumors," J. Immunol., 157(8):3550-3558 (1996).
~	Schofield, "Control of Chagas' disease vectors," <u>Brit. Med. Bull.</u> , <u>41</u> (2):187-194 (1985).
1	Schutze-Redelmeier et al., "Introduction of Exogenous Antigens into the MHC Class 1 Processing and Presentation Pathway by <i>Drosophila</i> Antennapedia Homeodomain Primes Cytotoxic T Cells In Vivo," <u>J. Immunol.</u> , <u>157</u> :650-655 (1996).
$\sim$	Schwarze et al., "In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse," <u>Science</u> , <u>285</u> (5433):1569-1572 (September 3, 1999).
N	Scott et al., " <sup>75</sup> Se-methionine labelled <i>Trypanosoma cruzi</i> blood trypomasitgotes: opsonization by chronic infection serum facilitates killing in spleen and liver," <u>Clin. Exp. Immunol.</u> , <u>48</u> :754-757 (1982).
1	Sedegah et al., "Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein," <u>Proc. Nat'l Acad. Sci. USA</u> , <u>91</u> (21):9866-9870 (1994).

EXAMINER	Date Considered
MARK NOVERED	6/16/03
	the september of the second se

OMB No. 0651-0011
Page 9 of 12

Group: Unas

INFORMATION TO THE DISCLOSURE STATEMENT

Page 9 of 12	
Serial No.: 09/518,156	

·	The state of the s	
1	Seifert et al., "Shuttle mutagenesis: A method of transposon mutagenesis for Saccharomyces cerevisiae," Proc. Natl. Acad. Sci. USA, 83:735-739 (1986).	
n	Sheibani, "Prokaryotic gene fusion expression systems and their use in structural and functional studies of proteins," <u>Prep. Biochem. Biotechnol.</u> , 29(1):77-90 (February 1999).	
	Shi et al., "Immunogenicity and <i>in vitro</i> protective efficacy of a recombinant multistage <i>Plasmodium falciparum</i> candidate vaccine," <u>Proc. Natl. Acad. Sci USA</u> , 96(4):1615-1620 (February 16, 1999).	
~	Silva et al., "Tumor Necrosis Factor Alpha Mediates Resistance to <i>Trypanosoma cruzi</i> Infection in Mice by Inducing Nitric Oxide Production in Infected Gamma Interferon-Activated Macrophages," <u>Infect. Immun.</u> , 63(12):4862-4867 (1995).	
~	Silva et al., "The role of IL-12 in experimental <i>Trypanosoma cruzi</i> infection," Braz. J. Med. Biol. Res., 31(1):111-115 (January 1998).	
~	Sin et al., "Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes," <u>Eur. J. Immunol.</u> , 28(11):3530-3540 (November 1998).	
1	Swinkels et al., "A phosphoglycerate kinase-related gene conserved between <i>Trypanosoma brucei</i> and <i>Crithidia fasciculata</i> ," Mol. Biochem Parasitol, 50:69-78 (1992).	
~	Tacket et al., "Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device," <u>Vaccine</u> , <u>17</u> (22):2826-2829 (July 16, 1999).	
1	Tarleton, "Depletion of CD8 <sup>+</sup> T cells increases susceptibility and reverses vaccine-induced immunity in mice infected with <i>Trypanosoma cruzi</i> ," <u>J. Immunol.</u> , <u>144(2):717-724 (1990)</u> .	
~	Tarleton et al., ""Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue," Proc. Natl. Acad. Sci. USA, 94(8):3932-3937 (1997).	
~	Tarleton et al., "Chagas Disease Etiology: Autoimmunity or Parasite Persistence?" Parasitol. Today, 15(3):94-99 (March 1999).	

Filing Date: 2 March 2000

EXAMINER	Date Considered
MARIC NAVARRO	6/16/03

~	Tarleton et al., "Vaccine Discovery and Testing in a Murine Model of American Trypanosomiasis," Abstract C10 Mem. Inst. Oswaldo Cruz, Rio de Janeiro, 94 (Suppl. II):17 (November, 1999).	
$\sim$	Teilhet et al., "Effect of short 5' <i>UTR</i> s on protein synthesis in two biological kingdoms," Gene, 222(1):91-97 (November 5, 1998).	
$\sim$	Tobin et al., "Transfected <i>Leishmania</i> Expressing Biologically Active IFN-γ," <u>J. Immunol.</u> , 150(11):5059-5069 (1993).	
	Torri et al., "A β-Like DNA Polymerase from the Mitochondrion of the Trypanosomatid <i>Crithidia fasciculata</i> ," J. Biol. Chem., 269(11):8165-8171 (1994).	
~	Trischmann, "Role of cellular immunity in protection against <i>Trypanosoma cruzi</i> in mice," <u>Parasite Immunol.</u> , <u>6</u> (6):561-570 (1984).	
$\sim$	Udenfriend et al., "How Glycosyl-Phosphatidylinositol-anchored membrane proteins are made," <u>Ann. Rev. Biochem.</u> , 64:563-591 (1995).	
	Ulmer et al., "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein," <u>Science</u> , <u>259</u> (5102):1745-1749 (1993).	
	Ullu et al., "Chapter 7: <i>Trans</i> -splicing in trypanosomatid protozoa," <u>Molecular Biology of Parasitic Protozoa</u> , Smith et al., eds., IRL Press, NY, Title page, publication page, and pages 115-133 (1996).	
$\sim$	Vanhamme et al., "Control of Gene Expression in Trypanosomes," Microbiol. Rev., 59(2):223-240 (1995).	
	Villalta et al., "Effects of human colony-stimulating factor on the uptake and destruction of a pathogenic parasite ( <i>Trypanosoma cruzi</i> ) by human neutrophils," J. Immunol., 137(5):1703-1707 (1986).	
	Voth et al., "Differentially expressed <i>Leishmania major gp63</i> genes encode cell surface leishmanolysin with distinct signals for glycosylphosphatidylinositol attachment," Mol. Biochem. Parasitol., 93(1):31-41 (May 15, 1998).	
~	Waisman et al., "Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity," Nature Med., 2(8):899-905 (1996).	
~	Wallace, "Flagellate parasites of mosquitos with special reference to <i>Crithidia fasciculata</i> léger 1902," J. Parasitol., 29:196-205 (1943).	

EXAMINER MANY MAYARAN	Date Considered
-----------------------	-----------------

~	Wang et al., "Simultaneous Induction of Multiple Antigen-Specific Cytotoxic T Lymphocytes in Nonhuman Primates by Immunization with a Mixture of Four <i>Plasmodium falciparum</i> DNA Plasmids," Infect. Immun., 66(9):4193-4202 (September, 1998).
$\sim$	Wang et al., "Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine," <u>Science</u> , <u>282</u> :476-480 (October 16, 1998).
$\sim$	Wirtz et al., "Inducible Gene Expression in Trypanosomes Mediated by a Prokaryotic Repressor," <u>Science</u> , <u>268</u> :1179-1183 (1995).
~	Wirtz et al., "Regulated processive transcription of chromatin by T7 RNA polymerase in <i>Trypanosoma brucei</i> ," Nuc.Acids Res., 26(20):4626-4634 (October 15, 1998).
1	Wirtz et al., "A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in <i>Trypanosoma brucei</i> " Mol. Biochem. Parasitol., 99(1):89-101 (March 15, 1999).
1	Wizel et al., "Induction of murine cytotoxic T lymphocytes against <i>Plasmodium</i> falciparum sporozoite surface protein 2," <u>Eur. J. Immunol.</u> , <u>24</u> (7):1487-1495 (1994).
2	Wizel et al., "Identification of <i>Trypanosoma cruzi Trans</i> -Sialidase Family Members as Targets of Protective CD8 <sup>+</sup> TC1 Responses," <u>J. Immunol.</u> , 159(12):6120-6130 (1997).
$\wedge$	Wizel et al., "Human Infection with <i>Trypanosoma cruzi</i> Induces Parasite Antigen-Specific Cytotoxic T Lymphocyte Responses," <u>J. Clin. Invest.</u> , 102(5):1062-1071 (September 1998).
1	Wizel et al., "Vaccination with Trypomastigote Surface Antigen 1-Encoding Plasmid DNA Confers Protection against Lethal <i>Trypanosoma cruzi</i> Infection," Infect. Immun., 66(11):5073-5081 (November 1998).
	Wrightsman et al., "Identification of Immunodependent Epitopes in <i>Trypanosoma cruzi</i> Trypomastigone Surface Antigen-1 Protein That Mask Protective Epitopes," J. Immunol., 153(7):3148-3154 (1994).
~	Xiang et al., "Vaccination with a Plasmid Vector Carrying the Rabies Virus Glycoprotein Gene Induces Protective Immunity against Rabies Virus," <u>Virology</u> , 199(1):132-140 (1994).

EXAMINER  MARY NAMERO	Date Considered 6 (60 3
-----------------------	-------------------------

	Xiang et al. "Manipulation of the	Immune Response to a Plasmid-Encoded Viral
~	Antigen by Coinoculation with Plasmids Expressing Cytokines," <u>Immunity</u> , <u>2(2):129-135 (1995)</u> .	
$\sim$	Yokoyama et al., "DNA Immunization Confers Protection against Lethal Lymphocytic Choriomeningitis Virus Infection," J. Virol., 69(4):2684-2688 (1995).	
~	Zhang et al., "The expression of biologically active human p53 in <i>Leishmania</i> cells: a novel eukaryotic system to produce recombinant proteins," Nuc. Acids Res., 23(20):4073-4080 (1995).	
$\sim$	Zhang et al., "Identification and overexpression of the A2 amastigote-specific protein in <i>Leishmania donovani</i> ," Mol. Biochem. Parasitol., 78:79-90 (1996).	
N	Zhang et al., "Loss of virulence in <i>Leishmania donovani</i> deficient in an amastigote-specific protein, A2," <u>Proc. Natl. Acad. Sci. USA</u> , <u>94</u> :8807-8811 (1997).	
EXAMINER		Date Considered
MANC NAVARRO		6/16/03
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in		

CONFORMANCE and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-FB-A820 Patent and Trademark Office, U.S. Department of Commerce (Also form PTO-1449)